Trials / Completed
CompletedNCT00861809
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
A Multicenter, Double-Blind, Randomized Placebo-Controlled Phase II Study to Evaluate the Pharmacodynamics, Safety, Tolerability, and PK of Single Doses of the Oral Motilin Receptor Agonist GSK962040, in Type 1 Diabetic Male and Female Patients With Gastroparesis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK962040 25 mg | 25 mg |
| DRUG | Placebo | placebo comparator |
| DRUG | GSK962040 50 mg | 50 mg |
| DRUG | GSK962040 1250 mg | 125 mg |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2009-03-13
- Last updated
- 2017-01-30
Locations
2 sites across 2 countries: Belgium, Sweden
Source: ClinicalTrials.gov record NCT00861809. Inclusion in this directory is not an endorsement.